FDA Authorizes Abbott's Libre Duo, First Device To Continuously Monitor Both Glucose And Ketones
The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes. The Libre Duo 10 Day is the first
Abbott got FDA approval for a new device that tracks two important things in blood instead of one—glucose and ketones. This shows Abbott is creating tools that help people with diabetes, which could attract more customers and make the company more valuable.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.